Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VSTM's Cash to Debt is ranked higher than
96% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. VSTM: No Debt )
VSTM' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
VSTM's Interest Coverage is ranked higher than
88% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VSTM: No Debt )
VSTM' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 19.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -52.99
VSTM's ROE (%) is ranked higher than
64% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. VSTM: -52.99 )
VSTM' s 10-Year ROE (%) Range
Min: -82.33   Max: -39.63
Current: -52.99

-82.33
-39.63
ROA (%) -48.97
VSTM's ROA (%) is ranked higher than
62% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. VSTM: -48.97 )
VSTM' s 10-Year ROA (%) Range
Min: -47.67   Max: -37.77
Current: -48.97

-47.67
-37.77
ROC (Joel Greenblatt) (%) -3188.24
VSTM's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. VSTM: -3188.24 )
VSTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7948.21   Max: -3102.26
Current: -3188.24

-7948.21
-3102.26
» VSTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

VSTM Guru Trades in Q1 2014

Jean-Marie Eveillard 511,254 sh (unchged)
Paul Tudor Jones 11,685 sh (-32.14%)
» More
Q2 2014

VSTM Guru Trades in Q2 2014

Jean-Marie Eveillard 512,254 sh (+0.20%)
Paul Tudor Jones Sold Out
» More
Q3 2014

VSTM Guru Trades in Q3 2014

Jim Simons 66,300 sh (New)
Jean-Marie Eveillard 512,254 sh (unchged)
» More
Q4 2014

VSTM Guru Trades in Q4 2014

Jim Simons 204,787 sh (+208.88%)
Jean-Marie Eveillard 302,622 sh (-40.92%)
» More
» Details

Insider Trades

Latest Guru Trades with VSTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.10
VSTM's P/B is ranked higher than
80% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. VSTM: 3.10 )
VSTM' s 10-Year P/B Range
Min: 0   Max: 4.9
Current: 3.1

0
4.9
EV-to-EBIT -4.85
VSTM's EV-to-EBIT is ranked higher than
73% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VSTM: -4.85 )
VSTM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.85

Current Ratio 10.36
VSTM's Current Ratio is ranked higher than
88% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. VSTM: 10.36 )
VSTM' s 10-Year Current Ratio Range
Min: 10.36   Max: 23.79
Current: 10.36

10.36
23.79
Quick Ratio 10.36
VSTM's Quick Ratio is ranked higher than
88% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. VSTM: 10.36 )
VSTM' s 10-Year Quick Ratio Range
Min: 10.36   Max: 23.79
Current: 10.36

10.36
23.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.31
VSTM's Price/Net Cash is ranked higher than
94% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. VSTM: 3.31 )
VSTM' s 10-Year Price/Net Cash Range
Min: 3.01   Max: 3.3
Current: 3.31

3.01
3.3
Price/Net Current Asset Value 3.21
VSTM's Price/Net Current Asset Value is ranked higher than
94% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. VSTM: 3.21 )
VSTM' s 10-Year Price/Net Current Asset Value Range
Min: 2.92   Max: 3.28
Current: 3.21

2.92
3.28
Price/Tangible Book 3.08
VSTM's Price/Tangible Book is ranked higher than
87% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. VSTM: 3.08 )
VSTM' s 10-Year Price/Tangible Book Range
Min: 1.98   Max: 3.87
Current: 3.08

1.98
3.87
Earnings Yield (Greenblatt) -20.90
VSTM's Earnings Yield (Greenblatt) is ranked lower than
57% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. VSTM: -20.90 )
VSTM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -60.4   Max: 0
Current: -20.9

-60.4
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2VS.Germany,
Verastem Inc was incorporated under the laws of the State of Delaware in August 2010. The Company is a biopharmaceutical company engaged in discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. A cancer stem cell is a particularly aggressive type of tumor cell, resistant to conventional cancer therapy, that it believes is an underlying cause of tumors, their recurrence and metastasis. It licenses its EMT technology from the Whitehead Institute for Biomedical Research, an affiliate of the Massachusetts Institute of Technology, or MIT, and the President and Fellows of Harvard College, or Harvard. Its advanced product candidates are VS-6063, VS-4718 and VS-5584. It is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including mesothelioma, ovarian and lung. The Company's solution is to discover and develop a next generation of oncology therapeutics targeting CSCs along with companion diagnostics. It believes that by developing therapeutics that target CSCs it can address the problem of cancer recurrence and metastasis. The Company has three product candidates currently in clinical trials including the focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718, and the dual mTORC1/2 and PI3K inhibitor VS-5584. The Company's competitors include Astellas Pharma Inc., Celgene, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc. and others. There are also biotechnology companies of various sizes that are developing therapies against CSCs, including OncoMed Pharmaceuticals, Inc., Boston Biomedical Inc. (a division of Dainippon Sumitomo Corp) and Stemline Therapeutics, Inc. and others. The Company is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.
» More Articles for VSTM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at... Apr 22 2015
Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at... Apr 22 2015
Coverage initiated on Verastem by H.C. Wainwright Apr 08 2015
Gelesis Closes $22M Equity Financing Mar 26 2015
Verastem to Present Data at the 2015 American Association of Cancer Research Annual Meeting Mar 19 2015
Verastem to Present Data at the 2015 American Association of Cancer Research Annual Meeting Mar 19 2015
VERASTEM, INC. Financials Mar 17 2015
Small Biotech Firm Quietly Makes +1,000% Price Move Mar 17 2015
Verastem (VSTM) Shares March Higher, Can It Continue? - Tale of the Tape Mar 10 2015
Verastem reports 4Q loss Mar 10 2015
Verastem reports 4Q loss Mar 10 2015
Verastem Reports Year-End 2014 Financial Results Mar 10 2015
VERASTEM, INC. Files SEC form 10-K, Annual Report Mar 10 2015
VERASTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 10 2015
Verastem Reports Year-End 2014 Financial Results Mar 10 2015
Biotech Company Could Be on the Cusp of New Proenzyme Drug for the Treatment and Prevention of... Mar 09 2015
Verastem to Present at 27th Annual ROTH Conference Mar 03 2015
Verastem to Present at 27th Annual ROTH Conference Mar 03 2015
Novartis, Verastem & Cepheid Making Biotech Headlines On Friday Feb 13 2015
Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma Feb 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK